Glial fibrillary acidic protein as a marker of astrocytic activation in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis

Felix Benninger*, Micaela J. Glat, Daniel Offen, Israel Steiner

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Glial fibrillary acidic protein (GFAP) has been shown to be increased in the cerebrospinal fluid (CSF) of patients suffering from neurological diseases involving the activation of astrocytes, but has not been studied in amyotrophic lateral sclerosis (ALS) patients to our knowledge. CSF samples of patients with definite ALS and of those with other neurological diseases were evaluated for their GFAP concentrations. CSF-GFAP concentrations of patients with ALS were significantly elevated by 53% compared to patients with other neurologic diseases. GFAP might serve as a biomarker in ALS. Our findings support the concept that astrocytes play a role in ALS pathogenesis.

Original languageEnglish
Pages (from-to)75-78
Number of pages4
JournalJournal of Clinical Neuroscience
Volume26
DOIs
StatePublished - 1 Apr 2016

Keywords

  • Amyotrophic lateral sclerosis
  • Astrocytes
  • Biomarker
  • GFAP
  • Motor neuron disease

Fingerprint

Dive into the research topics of 'Glial fibrillary acidic protein as a marker of astrocytic activation in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis'. Together they form a unique fingerprint.

Cite this